

EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in previously treated patients with nAMD

South Tyneside and Sunderland NHS Foundation Trust

These data are from real patients. Individual results may vary.

Study design:

Retrospective case series of 45 previously treated eyes with persistent suboptimal response to prior EYLEA 2 mg therapy, defined as ≥ 6 consecutive EYLEA 2 mg injections at 4- or 6-week intervals with persistent IRF and SRF on OCT despite treatment. Patients were switched from EYLEA 2 mg to EYLEA 8 mg between March 2024 and March 2025, with two or three loading doses at 4-week intervals. Regression models were used to identify predictors of clinical outcomes.

Patients were excluded if they had prior reactivation of nAMD on EYLEA 2 mg after several months off treatment; achieved treatment intervals longer than q6 on EYLEA 2 mg; were switched to faricimab 6 mg from EYLEA 2 mg before transitioning to EYLEA 8 mg; had other retinal comorbidities or recent ocular surgery; or had incomplete information.

Aim:

To evaluate anatomical and functional outcomes following a switch to EYLEA 8 mg in patients with nAMD exhibiting suboptimal response to EYLEA 2 mg.

Patient demographics

Eyes, N	45
Mean age, years	81.7
Female, %	56




21.4

Mean number of EYLEA 2 mg injections prior to switch

Anatomical improvements with EYLEA 8 mg vs. EYLEA 2 mg

Change in mean CMT through Month 12



A decrease in CMT after switching to EYLEA 8 mg from EYLEA 2 mg (N=45)
(Pre-switch: 305 [SD: 92.8] vs. post-switch: 269 [SD: 35.1]; $P=0.0039$)

Proportion of eyes with IRF (N=45)




Proportion of eyes with SRF (N=45)



51% (n=21/45) of eyes had no IRF or SRF after switching to EYLEA 8 mg

Maintained vision with EYLEA 8 mg

Mean change in VA through Month 12



+1.7 ETDRS letter

Change in VA after switching to EYLEA 8 mg (N=45)

The choice of loading regimen (two vs. three monthly loading doses) did not have an independent effect on clinical outcomes.

Adverse events: one case of elevated IOP was observed during this audit

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

*P-values are nominal as they are unadjusted, and not corrected for multiplicity or prespecified hypotheses.

Abbreviations:

CMT, central macular thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; qX, every X weeks; SmPC, Summary of Product Characteristics; SRF, subretinal fluid; VA, visual acuity; VEGF, vascular endothelial growth factor.

Reference:

Bayer UK Data on File_PP-EYL-GB-3025_November 2025

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

